219 related articles for article (PubMed ID: 21163583)
1. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma.
Narayana A; Kunnakkat SD; Medabalmi P; Golfinos J; Parker E; Knopp E; Zagzag D; Eagan P; Gruber D; Gruber ML
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):77-82. PubMed ID: 21163583
[TBL] [Abstract][Full Text] [Related]
2. Invasion is not an independent prognostic factor in high-grade glioma.
Narayana A; Perretta D; Kunnakkat S; Gruber D; Golfinos J; Parker E; Medabalmi P; Zagzag D; Pat Eagan RN; Gruber M
J Cancer Res Ther; 2011; 7(3):331-5. PubMed ID: 22044816
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab for the treatment of high-grade glioma.
Khasraw M; Simeonovic M; Grommes C
Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.
Narayana A; Kelly P; Golfinos J; Parker E; Johnson G; Knopp E; Zagzag D; Fischer I; Raza S; Medabalmi P; Eagan P; Gruber ML
J Neurosurg; 2009 Jan; 110(1):173-80. PubMed ID: 18834263
[TBL] [Abstract][Full Text] [Related]
5. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.
Shapiro LQ; Beal K; Goenka A; Karimi S; Iwamoto FM; Yamada Y; Zhang Z; Lassman AB; Abrey LE; Gutin PH
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):636-42. PubMed ID: 22765876
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.
Raizer JJ; Grimm S; Chamberlain MC; Nicholas MK; Chandler JP; Muro K; Dubner S; Rademaker AW; Renfrow J; Bredel M
Cancer; 2010 Nov; 116(22):5297-305. PubMed ID: 20665891
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.
Hofer S; Elandt K; Greil R; Hottinger AF; Huber U; Lemke D; Marosi C; Ochsenbein A; Pichler J; Roelcke U; Weder P; Zander T; Wick W; Weller M
Acta Oncol; 2011 Jun; 50(5):630-5. PubMed ID: 21495907
[TBL] [Abstract][Full Text] [Related]
10. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
[TBL] [Abstract][Full Text] [Related]
11. Irradiation and bevacizumab in high-grade glioma retreatment settings.
Niyazi M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; Geisler J; la Fougère C; Ertl L; Linn J; Siefert A; Belka C
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):67-76. PubMed ID: 21030162
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.
Drappatz J; Lee EQ; Hammond S; Grimm SA; Norden AD; Beroukhim R; Gerard M; Schiff D; Chi AS; Batchelor TT; Doherty LM; Ciampa AS; Lafrankie DC; Ruland S; Snodgrass SM; Raizer JJ; Wen PY
J Neurooncol; 2012 Mar; 107(1):133-8. PubMed ID: 21984064
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
Hwang EI; Jakacki RI; Fisher MJ; Kilburn LB; Horn M; Vezina G; Rood BR; Packer RJ
Pediatr Blood Cancer; 2013 May; 60(5):776-82. PubMed ID: 22976922
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
Bouffet E; Jakacki R; Goldman S; Hargrave D; Hawkins C; Shroff M; Hukin J; Bartels U; Foreman N; Kellie S; Hilden J; Etzl M; Wilson B; Stephens D; Tabori U; Baruchel S
J Clin Oncol; 2012 Apr; 30(12):1358-63. PubMed ID: 22393086
[TBL] [Abstract][Full Text] [Related]
15. Retrospective study of nivolumab for patients with recurrent high grade gliomas.
Mantica M; Pritchard A; Lieberman F; Drappatz J
J Neurooncol; 2018 Sep; 139(3):625-631. PubMed ID: 29779086
[TBL] [Abstract][Full Text] [Related]
16. Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.
Lombardi G; Zustovich F; Farina P; Fiduccia P; Della Puppa A; Polo V; Bertorelle R; Gardiman MP; Banzato A; Ciccarino P; Denaro L; Zagonel V
Anticancer Drugs; 2013 Jan; 24(1):90-7. PubMed ID: 23075631
[TBL] [Abstract][Full Text] [Related]
17. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.
Reardon DA; Herndon JE; Peters K; Desjardins A; Coan A; Lou E; Sumrall A; Turner S; Sathornsumetee S; Rich JN; Boulton S; Lipp ES; Friedman HS; Vredenburgh JJ
J Neurooncol; 2012 Mar; 107(1):213-21. PubMed ID: 21997879
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.
Nagane M; Nishikawa R; Narita Y; Kobayashi H; Takano S; Shinoura N; Aoki T; Sugiyama K; Kuratsu J; Muragaki Y; Sawamura Y; Matsutani M
Jpn J Clin Oncol; 2012 Oct; 42(10):887-95. PubMed ID: 22844129
[TBL] [Abstract][Full Text] [Related]
19. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
20. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.
Nagpal S; Recht CK; Bertrand S; Thomas RP; Ajlan A; Pena J; Gershon M; Coffey G; Kunz PL; Li G; Recht LD
J Neurooncol; 2015 Jun; 123(2):277-82. PubMed ID: 25935109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
